ARC Centre of Excellence in Convergent Bio-Nano Science and Technology

  • Davis, Thomas (Primary Chief Investigator (PCI))
  • Boyd, Benjamin (Chief Investigator (CI))
  • Bunnett, Nigel (Chief Investigator (CI))
  • Porter, Christopher (Chief Investigator (CI))
  • Caruso, Frank (Chief Investigator (CI))
  • Kent, Stephen (Chief Investigator (CI))
  • Thordarson, Pall (Chief Investigator (CI))
  • Kearnes, Matthew (Chief Investigator (CI))
  • Gooding, John (Chief Investigator (CI))
  • Kavallaris, Maria (Chief Investigator (CI))
  • Thurecht, Kristofer (Chief Investigator (CI))
  • Whittaker, Andrew K. (Chief Investigator (CI))
  • Parton, Robert (Chief Investigator (CI))
  • Corrie, Simon Robert (Chief Investigator (CI))
  • Johnston, Angus (Chief Investigator (CI))
  • McGhee, John (Chief Investigator (CI))
  • Greguric, Ivan D. (Partner Investigator (PI))
  • Stevens, Molly Morag (Partner Investigator (PI))
  • Lewis, Jason S. (Partner Investigator (PI))
  • Lee, Doo Sung (Partner Investigator (PI))
  • Alexander, Cameron (Partner Investigator (PI))
  • Dawson, Kenneth (Partner Investigator (PI))
  • Hawker, Craig (Partner Investigator (PI))
  • Haddleton, David (Partner Investigator (PI))
  • Thierry, Benjamin (Chief Investigator (CI))
  • Prestidge, Clive Allan (Chief Investigator (CI))
  • Meyer, Anne (Project Manager)
  • Jones-Jayasinghe, Natalie (Project Manager)
  • Voelcker, Nicolas (Chief Investigator (CI))
  • Nann, Thomas (Chief Investigator (CI))
  • McLean, Keith (Partner Investigator (PI))

Project: Research

Project Details

Project Description

The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on
research aiming to understand and control the interface of materials with biological systems. The Centre will
exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs
and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp
of revolutionizing diagnosis and therapy in many diseases. The CoE will be the focus of bio-nano research
activity in Australia, uniting universities, research agencies, institutes and companies. The expected
outcomes are better diagnostic and therapeutic tools designed via an enhanced understanding of the bionano-
Effective start/end date30/06/1429/06/21


  • Australian Research Council (ARC): A$134,500.00
  • Australian Research Council (ARC): A$1,890,000.00
  • Australian Research Council (ARC): A$1,890,000.00
  • Australian Research Council (ARC): A$1,890,000.00
  • Australian Research Council (ARC): A$945,000.00
  • Australian Research Council (ARC): A$945,000.00
  • Australian Research Council (ARC): A$1,108,422.00
  • Monash University: A$2,625,049.00
  • Australian Research Council (ARC): A$17,197,080.00
  • University of Melbourne: A$2,331,000.00
  • University of New South Wales (UNSW): A$1,575,000.00
  • University of Queensland : A$2,012,554.00
  • University of South Australia: A$868,000.00
  • Monash University – Internal Faculty Contribution
  • University of Wisconsin Madison
  • Memorial Sloan Kettering Cancer Center
  • University of California System
  • University College Dublin
  • Imperial College London
  • University of Warwick
  • SungKyunKwan University
  • Australian Nuclear Science and Technology Organisation (ANSTO)
  • University of Nottingham